Publications by authors named "Michael D Robbins"

Claim this Profile
A
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma.
Tatiana Pazina, Alexander W MacFarlane, Luca Bernabei, Essel Dulaimi, Rebecca Kotcher, Michael D Robbins

Cancers (Basel)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
Irene M Ghobrial, Chia-Jen Liu, Robert A Redd, Raymond P Perez, Rachid Baz, Michael D Robbins

Clin Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Tatiana Pazina, Ashley M James, Kimberly B Colby, Yibin Yang, Andrew Gale, Michael D Robbins

Cancer Immunol Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
Ahmed T Kurdi, Siobhan V Glavey, Natalie A Bezman, Amy Jhatakia, Jennifer L Guerriero, Michael D Robbins

Mol Cancer Ther· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Kenneth C Anderson, Daniel Auclair, Gary J Kelloff, Caroline C Sigman, Hervé Avet-Loiseau, Michael D Robbins

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
Tatiana Pazina, Ashley M James, Alexander W MacFarlane, Natalie A Bezman, Karla A Henning, Michael D Robbins

Oncoimmunology· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.
Natalie A Bezman, Amy Jhatakia, Alper Y Kearney, Ty Brender, Mark Maurer, Michael D Robbins

Blood Adv· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab.
Jennifer Postelnek, Robert J Neely, Michael D Robbins, Carol R Gleason, Jon E Peterson

AAPS J· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balaji Balasa, Rui Yun, Nicole A Belmar, Melvin Fox, Debra T Chao, Michael D Robbins

Cancer Immunol Immunother· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.
Michael J Munchhof, Qifang Li, Andrei Shavnya, Gary V Borzillo, Tracey L Boyden, Michael D Robbins

ACS Med Chem Lett· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals.
Julie L Hawkins, Michael D Robbins, Laurie C Warren, Donghui Xia, Stephen F Petras

J Pharmacol Exp Ther· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aminopyrrolidineamide inhibitors of site-1 protease.
Bruce A Hay, Barbara Abrams, Allice Y Zumbrunn, James J Valentine, Laurie C Warren, Michael D Robbins

Bioorg Med Chem Lett· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis